Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox

The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.

What was the primary mode of smallpox transmission? Implications for biodefense

This review examines evidence from the history of variolation, data on mucosal infection collected in the last decades of smallpox transmission, aerosol measurements, animal models, reports of smallpox lung among healthcare workers, and the epidemiology of smallpox regarding the potential importance of fine particle aerosol mediated transmission.

Exercise Mataika: White Paper on response to a smallpox bioterrorism release in the Pacific

A smallpox epidemic in the Pacific could spread globally and could be challenging to contain due to dispersed island geography, informal maritime travel and shortage of human resources. In this context, a smallpox simulation exercise was held in August 2018, with a focus on bringing together international stakeholders from a wide range of sectors including health, defence, law enforcement, emergency management and relevant non-government organizations.

HHS sponsors new formulation of world’s first approved smallpox drug

To expand US health security and prepare for the potential use of smallpox virus in bioterrorism attacks against the United States, the US Department of Health and Human Services (HHS) will purchase additional doses of a smallpox antiviral medication called TPOXX for the Strategic National Stockpile and will work with Siga Technologies to develop an intravenous formulation of the drug.